Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11617657 | 0.95 | PRKCA (0.45) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216700 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216717 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216704 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL4603438 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL31216699 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL17627885 | 0.93 | PRKCA (0.48) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL9776393 | 0.86 | PRKCA (0.33) | PRKCAGLS2TSHRTRPV1MAPT | |
| SCHEMBL8058797 | 0.86 | TSHR (0.39) | PRKCATSHRCTSKMAPTMAPK1 | |
| SCHEMBL7593898 | 0.86 | TSHR (0.39) | PRKCATSHRCTSKMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586883-B2 | Aldehyde-selective wacker-type oxidation of unbiased alkenes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586883-B2 | Aldehyde-selective wacker-type oxidation of unbiased alkenes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586883-B2 | Aldehyde-selective wacker-type oxidation of unbiased alkenes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140316149-A1 | ALDEHYDE-SELECTIVE WACKER-TYPE OXIDATION OF UNBIASED ALKENES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140316149-A1 | ALDEHYDE-SELECTIVE WACKER-TYPE OXIDATION OF UNBIASED ALKENES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140316149-A1 | ALDEHYDE-SELECTIVE WACKER-TYPE OXIDATION OF UNBIASED ALKENES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-23 | — | — | US | disclosed |
| US-7786304-B2 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-20080146800-A1 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146800-A1 | Process for the preparation of eszopiclone | CYP3A5, CYP3A7, CYP51A1 | PRKCA 3210/4885GLS2 3884/4885TSHR 2936/4885 |
| US-20140316149-A1 | ALDEHYDE-SELECTIVE WACKER-TYPE OXIDATION OF UNBIASED ALKENES | AOC2, ALDH2, ALDH3A1 | PRKCA 1046/4885GLS2 1054/4885TSHR 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.